Germany’s primary health authority has warned that proposed registry laws must be significantly strengthened to ensure data are robust enough for pharmaceutical benefit assessments.
A new proposal by Germany’s health quality institute suggests pharmaceutical companies should pay a 1 per cent turnover tax to sustain the nation’s medical register infrastructure.
